ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Please provide your email address to receive an email when new articles are posted on . Patients with IBD who received rapid infusions of infliximab were not at elevated risk for infusion reaction ...

Infliximab is medicine used for many inflammatory or immune problems, such as certain types of arthritis, gut conditions, and skin conditions. Common side effects include infections, headache, or ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

To reduce the burden of individuals traveling long distances to receive hospital infusions or for families who are juggling care for several children and possibly older adult relatives, many ...

July 11, 2002 -- The U.S. Food and Drug Administration (FDA) has granted marketing approval to infliximab (Remicade) to provide long-term remission-level control of moderate to severe Crohn's disease.

In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...

Bethesda, MD (Sept. 5, 2014) — Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

LAS VEGAS -- Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) ...

Infliximab is used to treat a variety of inflammatory disorders; however, infusion reactions can occur that might necessitate discontinuation of treatment. A study in Sweden has evaluated the ...

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohn’s disease, conclude authors of a study in this week’s issue of THE LANCET. Crohn’s disease is a ...